Stocklytics Platform
Asset logo for symbol CSTL
Castle Biosciences
CSTL65
$28.26arrow_drop_up2.41%$0.66
Asset logo for symbol CSTL
CSTL65

$28.26

arrow_drop_up2.41%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Castle Biosciences (CSTL) Stocklytics Forecast

Castle Biosciences Inc (CSTL) is a leading molecular diagnostics company focused on providing diagnostic and prognostic solutions for patients with rare and difficult-to-diagnose cancers. With cutting-edge technologies and innovative approaches, Castle Biosciences has established itself as a trusted name in the field of personalized medicine. The company's flagship product, DecisionDx-Melanoma, is designed to predict the risk of melanoma recurrence and help guide treatment decisions. With a market-leading position and a strong pipeline of new products, Castle Biosciences is well positioned for future growth.
As for the stock price forecast for Castle Biosciences Inc (CSTL), it is important to note that predicting stock prices is inherently uncertain and subject to various factors and market conditions. However, analysts and experts have expressed positive sentiments about the company's prospects. Based on their analysis, the consensus price target for CSTL stock for the year 2023 is $75. This target reflects the analysts' belief in the company's ability to deliver strong financial performance and maintain its market leadership.
add Castle Biosciences  to watchlist

Keep an eye on Castle Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Castle Biosciences (CSTL) stock?

Analysts have set a target price of $44.95 for Castle Biosciences (CSTL), based on forecasts from 21 analysts. The predicted price range extends from a high of $85 to a low of $25. This represents a potential increase of up to 200.71% and a decrease of -11.55% from the current price of $28.27. These forecasts are as of 2021 Apr 30.
help

What are the analyst ratings for Castle Biosciences (CSTL) stock?

The analyst ratings for Castle Biosciences (CSTL) are distributed as follows: 9 analysts recommend buying, 0 have a neutral stance, and 0 suggest selling. There is a split consensus, with equal support for two of the rating categories. These ratings indicate the general sentiment among the analysts covering Castle Biosciences .
help

What is the AI price prediction for Castle Biosciences (CSTL) stock?

At present, there is no AI or machine-learning-based price prediction available for Castle Biosciences (CSTL) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level